Inviragen Finds New Life For Shelved Japanese Encephalitis Vaccine At State-Owned VABIOTECH
This article was originally published in PharmAsia News
A vaccine project put on the shelf – after better-funded Intercell won regulatory approval for a rival product – has found a new home in Vietnam at a state-owned company looking to keep costs in check.
You may also be interested in...
SINGAPORE - Inviragen (Singapore) Pte Ltd is recruiting patients for its Phase I clinical trial in Singapore for its hand, foot and mouth disease vaccine INV21
SingVax Merges With Inviragen To Raise $15 Million In Series-A Financing For Vaccines To Fight Infectious Disease
SINGAPORE - U.S.-based Inviragen and Singapore-based SingVax unveiled plans to merge their companies' vaccine pipelines to form a new entity known as Inviragen (Singapore) to develop vaccines for a range of infectious diseases including dengue fever, Japanese encephalitis and hand, foot and mouth disease
Seoul-based IVI Partners With Indian Shantha Biotechnics For Low-Cost Cholera Vaccine Licensed in India
SEOUL - A new oral cholera vaccine developed by Seoul-based International Vaccine Institute has been licensed to India's Shantha Biotechnics, paving the way for worldwide use of a low-cost cholera vaccine in developing countries, where most cholera cases occur, the IVI said